Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker, Evelien W
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Mar 2009 - 2048-57 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-08-1535 doi
Animals
Antineoplastic Agents--pharmacology
Caspase 3--metabolism
Cell Line, Tumor
Cisplatin--pharmacology
Female
Humans
Luminescent Measurements
Mice
Ovarian Neoplasms--drug therapy
Receptors, TNF-Related Apoptosis-Inducing Ligand--metabolism
Recombinant Proteins--pharmacology
TNF-Related Apoptosis-Inducing Ligand--pharmacokinetics
Tissue Distribution
Xenograft Model Antitumor Assays
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Mar 2009 - 2048-57 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-08-1535 doi
Animals
Antineoplastic Agents--pharmacology
Caspase 3--metabolism
Cell Line, Tumor
Cisplatin--pharmacology
Female
Humans
Luminescent Measurements
Mice
Ovarian Neoplasms--drug therapy
Receptors, TNF-Related Apoptosis-Inducing Ligand--metabolism
Recombinant Proteins--pharmacology
TNF-Related Apoptosis-Inducing Ligand--pharmacokinetics
Tissue Distribution
Xenograft Model Antitumor Assays